Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Modelling in economic evaluation: an unavoidable fact of life.

Literature DB >> 9226140

Modelling in economic evaluation: an unavoidable fact of life.

M J Buxton, M F Drummond, B A Van Hout, R L Prince, T A Sheldon, T Szucs, M Vray.

Abstract

The role of modelling in economic evaluation is explored by discussing, with examples, the uses of models. The expanded use of pragmatic clinical trials as an alternative to models is discussed. Some suggestions for good modelling practice are made.

Mesh：

Year: 1997 PMID： 9226140 DOI： 10.1002/(sici)1099-1050(199705)6:3<217::aid-hec267>3.0.co;2-w

Source DB: PubMed Journal: Health Econ ISSN： 1057-9230 Impact factor: 3.046

Keyword Cloud
Cited

143 in total

1. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.

Authors: D M Pickin; C J McCabe; L E Ramsay; N Payne; I U Haq; W W Yeo; P R Jackson
Journal: Heart Date: 1999-09 Impact factor: 5.994

Review 2. Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making.

Authors: R Baltussen; R Leidl; A Ament
Journal: Pharmacoeconomics Date: 1999-11 Impact factor: 4.981

3. Costs of diabetes. A methodological analysis of the literature.

Authors: E Pagano; M Brunetti; F Tediosi; L Garattini
Journal: Pharmacoeconomics Date: 1999-06 Impact factor: 4.981

Review 4. Selecting a decision model for economic evaluation: a case study and review.

Authors: J Karnon; J Brown
Journal: Health Care Manag Sci Date: 1998-10

Review 5. Accounting for noncompliance in pharmacoeconomic evaluations.

Authors: D A Hughes; A Bagust; A Haycox; T Walley
Journal: Pharmacoeconomics Date: 2001 Impact factor: 4.981

Review 6. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application.

Authors: M Sculpher; E Fenwick; K Claxton
Journal: Pharmacoeconomics Date: 2000-05 Impact factor: 4.981

Modelling in economic evaluation: an unavoidable fact of life.

1. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.

Review 2. Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making.

3. Costs of diabetes. A methodological analysis of the literature.

Review 4. Selecting a decision model for economic evaluation: a case study and review.

Review 5. Accounting for noncompliance in pharmacoeconomic evaluations.

Review 6. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application.

Review 7. Modelling in health economic evaluation. What is its place? What is its value?

Review 8. Handling uncertainty in cost-effectiveness models.

Review 9. Testing the validity of cost-effectiveness models.

10. Computer modelling. The need for careful evaluation and public audit.